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ABSTRACT
Introduction The optimal management of small- sized 
to medium- sized vestibular schwannoma (VS) is a matter 
of controversy. Clinical results of the prevailing treatment 
modalities (microsurgery, stereotactic radiosurgery (SRS), 
and conservative management (CM)) are documented, but 
comparative studies are few, and none are randomised 
or blinded. Upfront radiosurgery, or a careful follow- up 
by MRI with subsequent treatment on growth, are two 
strategies used at many centres. The present study aims 
at comparing these strategies by randomising individuals 
with newly diagnosed tumours to either upfront SRS or 
initial CM.
Methods and analysis The Vestibular Schwannoma: 
Radiosurgery or Expectation study is designed as a 
randomised, controlled, observer- blinded, single- centre 
superiority trial with two parallel groups. Eligible patients 
will be randomised using sequentially numbered opaque 
sealed envelopes, and the radiosurgery group will undergo 
standard Gamma Knife Radiosurgery (GKRS) within 2 
months following randomisation. The primary endpoint is 
tumour growth measured as volume ratio V4years/Vbaseline and 
volume doubling time, evaluated by annual T1 contrast 
MRI volumetric analysis. Secondary endpoints include 
symptom and sign development measured by clinical 
examination, audiovestibular tests, and by patient’s 
responses to standardised validated questionnaires. In 
addition, the patient’s working status, and the health 
economics involved with both strategies will be evaluated 
and compared. All outcome assessments will be performed 
by blinded observers. Power analysis indicates that 100 
patients is sufficient to demonstrate the effect of GKRS on 
tumour volume.
Ethics and dissemination The trial has ethical approval 
from the Regional Ethical Committee (23503) and funding 
from The Western Norway Regional Health Authority. Trial 
methods and results will be reported according to the 
Consolidated Standards of Reporting Trials 2010 guidelines 
in a peer- reviewed journal.
Trial registration number Clinical trials: NCT02249572. 
Haukeland University Hospital record: 2014/314. Regional 
Ethical Committee (REC West): 23 503. The Western 
Norway Regional Health Authority: 912 281.
INTRODUCTION
Background and rationale
Vestibular schwannomas (VS) are benign 
neoplasms arising from the Schwann cells of 
the vestibulocochlear nerve.1 With an inci-
dence of approximately 2 per 100 000 individ-
uals annually, they account for 6%–8% of all 
intracranial neoplasms and 80%–90% of all 
cerebellopontine angle lesions.2 3 The hall-
mark symptoms of VS are unilateral hearing 
loss, tinnitus, vertigo and unsteadiness, 
caused by the tumour interfering with the 
audiovestibular system. In a minority of cases, 
larger tumours may affect cerebrospinal fluid 
diversion or impact neighbouring cranial 
Strengths and limitations of this study
 ► The Vestibular Schwannoma: Radiosurgery or 
Expectation is the first randomised controlled trial 
on vestibular schwannoma.
 ► This study presents an explicit and replicable meth-
odology to analyse the effect of radiosurgery on ves-
tibular schwannomas.
 ► Four- year annual follow- up with radiological, clini-
cal, audiovestibular and quality- of- life assessments.
 ► Radiological follow- up will include three- 
dimensional volumetric tumour measurements for 
precise growth analysis.
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nerves, the brain stem and cerebellum, and thus cause a 
wider range of symptoms.4
VS are usually slow- growing, with mean growth rates 
typically being reported at around 1–2 mm/year, with 
30%–70% of cases increase in size within 5 years of diag-
nosis.5–7 In modern healthcare societies, VS are not 
expected to cause shortening of the life expectancy. 
However, it affects the individuals’ functional capacity 
and quality of life (QOL) to a considerable degree and 
many affected individuals are put out of work as a result 
of chronic problems.8–11
Following diagnosis, three management options are 
considered routine treatment; microsurgical resec-
tion (MS), stereotactic radiosurgery (SRS) and conser-
vative management (CM) with serial imaging and 
clinical follow- up.12 Large tumours are removed surgically 
because of mass effect and this is not disputed. However, 
an ever- increasing majority of the patients are presenting 
with smaller tumours as a result of increased MRI access.3 
For these, the initial treatment options are controversial. 
They may be summarised as follows:
1. Conservative management (‘Watchful waiting’) by seri-
al MRI scanning. Treatment only if evidence of growth, 
given as:
a. stereotactic radiosurgery and
b. microsurgical resection.
2. Immediate treatment at diagnoses, given as:
a. SRS and
b. microsurgical resection.
Regarding the more active treatment strategies (radio-
surgery vs microsurgery), there is disagreement in the 
literature about the best way to treat a patient with small 
sized and medium- sized VS. There are two level II studies 
comparing microsurgery (MS) and SRS; Pollock (2006) 
and our own Myrseth (2009).2 13 Both show a higher 
proportion of treatment- associated morbidity with micro-
surgery. There are also several level III studies supporting 
the use of radiosurgery instead of microsurgery.14 15 
Therefore, the collected evidence is somewhat favouring 
SRS above MS as primary treatment, although this is a 
highly debated and controversial topic given the lack of 
high- impact, scientific evidence.
There are however little data to guide us in advising the 
patient of SRS or CM given the tumour is small. There is 
no level I evidence; however, there are two level II studies 
worldwide comparing 1a and 2a, including one from our 
group.16 17
A French study by Regis et al comparing radiosurgery and 
CM in very small tumours concluded that growth was evident 
in nearly all cases in the observational group.16 Growth was 
stopped in the GKRS group, but hearing outcomes were 
not better in the treated cases than in observed. Our own 
study of small- sized and medium- sized tumours found no 
difference in the risk of developing unilateral hearing loss 
in the two groups as the vast majority of patients had lost 
hearing by 5 years. However, we found a highly significant 
growth reduction caused by GKRS, as well as a highly signif-
icant reduction of patients undergoing retreatment.17
There is a growing debate on how VS can be best 
treated as it has become clear that the tumour may remain 
unchanged in size for years following diagnosis.12 18 Our 
own prospective study using volumetric measurements 
indicate that growth may be detected in 60%–80% of 
cases over a 4.5- year period, but it is of less significance 
in many cases, leading to treatment only in 41%.7 A 
careful follow- up by MRI, the so- called ‘wait and scan’ or 
‘watchful waiting’, has therefore emerged as a safe way of 
CM in patients with VS with small- sized and medium- sized 
tumours.
Our VS multidisciplinary team has during the last 15 
years recommended CM for standard initial treatment 
in small- sized and medium- sized tumours (alternative 
1), followed by radiosurgery (alternative 1a) in cases of 
tumour growth. In the same period, we have studied treat-
ment efficacy, symptom relief, QOL and work capacity, 
and documented our outcomes in a series of comparative 
studies providing evidence at level II and III.2 6–10 17–30
The present study aims at comparing the two modal-
ities by randomising patients with newly diagnosed 
VS to either CM or immediate radiosurgery. The aim 
of treatment is to stop further tumour growth; there-
fore, the primary study endpoint is the relative tumour 
size measured as the ratio between tumour volume at 
4 years compared with volume at inclusion. However, it 
is uncertain whether treatment leads to any other partic-
ular advantage than arresting further growth. Thus, 
secondary endpoints include symptom and sign devel-
opment measured by both objective (‘doctor- observed’) 
and subjective (‘patient- reported’) measures, clinical 
examination and by patients' responses to standardised 
validated questionnaires. In addition, health economics 
involved with both strategies will be evaluated, including 
the patients working status.
Objectives
The null hypothesis (H0) is that Gamma Knife Radiosur-
gery (GKRS) given to a small VS produces no difference 
in the growth rate of the tumour (primary endpoint) or 
clinical parameters (secondary endpoints), in particular 
hearing, compared with untreated patients within a time 
frame of 4 years.
The primary objective is to document the potential 
effect of upfront radiosurgery VS observation. We will 
measure and compare the tumour growth rate expressed 
as the change in tumour volume over a 4- year period.
Secondary objectives:
 ► Clarify whether GKRS treatment causes less or more 
decline in hearing acuity than what is found after the 
conservative approach, that is, the natural develop-
ment of symptoms. These measures will be measured 
and compared using standard pure- tone audiometry 
and speech discrimination (reported according to 
the Gardner- Robertson hearing classification scales 
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Table 1 WHO registration data set
Title Protocol for a randomised, observer- blinded study to 
compare the impact of up- front radiosurgery versus 
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Intervention name: Gamma Knife Radiosurgery
Intervention description: Patients receiving radiosurgery 
undergo treatment within 2 months following 
randomisation. Radiosurgery is given according to a 
standard dose plan of 12 Gy to the tumour periphery. The 
maximal dose, number of shots and the brainstem and 
cochlea doses are reported.
Intervention type: diagnostic test
Intervention name: MRI
Intervention description: gadolinium- enhanced T1- 
weighted MRI.
Intervention type: diagnostic test






Intervention description: patients undergoing observational 
treatment are assigned to annual clinical and radiological 
follow- up.
Intervention type: diagnostic test
Intervention name: MRI
Intervention description: gadolinium- enhanced T1- 
weighted MRI.
Intervention type: diagnostic test




Age eligibility: 18–70 years
Sex eligibility: both
Accepts healthy volunteers: no
Inclusion criteria:
Newly diagnosed vestibular schwannoma by MRI of less 
than 6 months with cerebellopontine angle (CPA) diameter 
less than 20 mm
Exclusion criteria:
1.Type II neurofibromatosis in patient or first grade relative.
2.Severe comorbidity
3.Unwilling/not fit for participation for other reasons (ex. 
alcohol abuse, personality disorder, language problems)
Study design Study type: interventional trial
Allocation: randomised
Intervention model: parallel group
Primary purpose: treatment
Phase: N/A
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 ► Assess the effect of GKRS on postural balance and 
vestibular nerve function by applying a standardised 
panel of vestibular function tests (dynamic posturog-
raphy and caloric test), compared with that caused by 
the natural course of the tumour.
 ► Detect differences in QOL by applying a panel of 
standardised and validated questionnaires directed 
against tumor- related symptoms.
Trial design
The Vestibular Schwannoma: Radiosurgery or Expectation 
(V- REX) is designed as a randomised, controlled, observer- 
blinded, single- centre, superiority trial with two parallel 
groups. Bloc randomisation is performed with 1:1 alloca-
tion. The primary endpoint is tumour growth measured as 
volume ratio V4years/Vbaseline and volume doubling time (VDT), 
evaluated by annual T1 contrast MRI volumetric analysis for 
4 years. The study follows an intention- to- treat paradigm. 
Conservatively managed patients with tumour growth that 
prompts more active treatment following observations will 
cross over from the conservative to the GKRS group (or 
treated by microsurgical methods); however, they will be 
assigned to their original group. The same applies to patients 
with a growing tumour despite GKRS that are treated with 
salvage microsurgery or repeated GKRS. Patients who refrain 
from radiosurgery despite randomisation will be excluded, as 
patients must adhere to the study randomisation.
 
Trial summary




The Haukeland University Hospital in Bergen, Norway, 
has the national treatment responsibility of all patients 
with VS in Norway. This Norwegian National Unit for 
Vestibular Schwannomas is a cooperation between the 
Department of Neurosurgery and the Department of 
Head- and- Neck Surgery. Approximately 120 patients with 
a newly diagnosed VS per year are referred, and since 
2001, all patients are included in a prospectively main-
tained VS database (REC 114/01).
All V- REX participants will be annually observed for 4 
years, and the study is expected to be completed in 2022, 
7–8 years after randomisation.
Eligibility criteria
Inclusion criteria
Newly diagnosed VS by MRI of less than 6 months with 
cerebellopontine angle (CPA) diameter less than 20 mm.
Exclusion criteria
1. Type II neurofibromatosis in patient or first- grade 
relative.
2. Severe comorbidity (ex. dementia, active malignant 
disease).
3. Unwilling/not fit for participation for other reasons 




Eligible patients will be randomised in equal proportions 
between GKRS (trial group A) and Observation (trial 
group B).
Gamma Knife Radiosurgery (trial group A)
Patients receiving radiosurgery undergo standard radio-
surgical treatment within 2 months following randomisa-
tion. Radiosurgery is given according to a standard dose 
plan of 11–14 (typically 12) Gy to the tumour margin 
at the 40%–55% isodose line. The maximum dose, the 
number of isocentres, and maximum dose to the brain-
stem and modulus of cochlea are reported. Our treat-
ment center utilises the Elekta Gamma Knife Perfexion 
– with a planned upgrade to Icon in September 2019.
Observation group (trial group B)
Patients undergoing observational treatment are assigned 
to annual clinical and radiological follow- up.
Other interventions
Any additional treatment of a tumour or tumor- related 
conditions or problems (such as VP shunt for hydroceph-
alus) will be reported.
Modifications
Potential conversion from observation to treatment 
during the study period will entirely be based on the 
Primary 
outcomes
Outcome: growth measured as volume ratio V4years/Vbaseline 





Outcome: subjective complaints assessed by observer- 
blinded clinical follow- ups and questionnaires
Timeframe: 4 years
Outcome: Penn Acoustiv Neuroma Quality- of- Life 
(PANQOL) scale
Timeframe: 4 years
Outcome: EuroQol 5 Dimension 3 Level Response (EQ- 
5D- 3L)
Timeframe: 4 years
Outcome: Hearing acuity according to Gardner Robertson 
scale (safety endpoint)
Timeframe: 4 years
Outcome: posturography and caloric function
Timeframe: 4 years
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assessment of the treating clinician only, completely 
autonomously from the study physicians.
Adherence
High adherence is expected, as the participants are invited 
to only four annual study visits. All travel and subsistence 
expenses are covered by the project, and all participants 
will be provided paid sick leave. If necessary, participants 
will be offered the option of a telephonic follow- up.
Concomitant care
No concomitant care or interventions are permitted or 
prohibited during the trial.
Outcomes
Primary endpoint
Tumour growth, measured as volume ratio (V4years / Vbase-
line) and 1/VDT
-1. Tumour volume will be measured on 
T1 contrast MRI scans with 2 mm slice interval/thickness. 
The measurement is to be done by a blinded observer.
Secondary endpoint
 ► Subjective problems and clinical examinations 
assessed by a blinded questionnaire.
 ► Audiovestibular tests
 – Hearing acuity according to Gardner Robertson 
scale (safety endpoint).
 – Balance platform.
 – Nystagmometry.
 ► Patient- reported outcome measures
 – PANQOL.
 – EuroQol 5 Dimension 3 Level Response 
(EQ- 5D- 3L).
 – Health Economy (main source of income, annu-
al total income, sick leave and use of healthcare 
system).
 ► Conversion to other treatment during the study 
period.
 ► Adverse effects.
Participant timeline
The time schedule of enrolment, interventions, assess-
ments and visits for participants is presented in table 2.
Sample size
We performed two power analyses based on data from 
our own VS database.
Based on hearing outcomes
In the first power analysis, we examined the number of 
patients needed to demonstrate if the two groups would 
be similar or different in hearing outcome (figures 1–3).
Test for difference:
Power
(1—type 2 error): 0.8 or 0.9
The probability of reject H0 
when H0 is false
Type 1 error: 0.05 The probability of reject H0 
when H0 is true
Table 2 Participant timeline




<6 months from 
diagnosis
Treatment 











  Eligibility screen X             
  Informed consent X             
  Allocation   X           
Interventions
  Gamma knife radiosurgery     X Intervention 
group only
        
Assessments
  MRI X     X X X X
  Tumour volumetric measurements   X   X X X X
  Clinical examinations   X   X X X X
  Audiometry   X   X X X X
  Dynamic posturography   X   X X X X
  Video- nystagmometry   X   X X X X
  Penn acoustic neuroma qualify- of- 
life questionnaire
  X   X X X X
  EQ- 5D- 3L Questionnaire   X   X X X X
  Health economy/ working status   X   X X X X
EQ- 5D- 3L, EuroQol 5 Dimension 3 Level Response. copyright.
 on N
ovem
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One usually wants a power of 80% or more and a low 
type 1 error.
Scenario 1—difference in proportions (Gardner-Robertson)
We want to determine the sample size for a 5- year VS trial 
with Gamma Knife therapy and a control group with no 
treatment. The primary outcome is hearing loss, defined 
as useful to no useful hearing (binary outcome). We 
desire a 0.05- significance level test with 90% statistical 
power. The proportion of no useful hearing at a 5- year 
follow- up in a similar population is 54%. We plan to have 
an equal allocation to the two treatment groups.
Scenario 2—difference in means (% of perfect hearing)
We want to determine the sample size for a 5- year VS trial 
with Gamma Knife therapy and a control group with no 
treatment. The primary outcome is hearing loss, defined 
as the percentage of perfect hearing (100% excellent 
hearing and 0% deaf). We desire a 0.05 significance level 
test with 90% statistical power. The SD observed from a 
similar population is 35. We plan to have an equal alloca-
tion to the two treatment groups.
Test for equivalence:
Power
(1—type 2 error): 0.90 or 0.95
The probability of 
reject H0 when H0 is 
false
Type 1 error: 0.10 The probability of 
reject H0 when H0 is 
true
One usually wants a higher power (90% or more) and 
a higher type 1 error.
Scenario 3—equivalence in means (% of perfect hearing)
We want to determine the sample size for a 5- year VS 
equivalence trial with Gamma Knife therapy and a 
control group with no treatment. The primary outcome is 
hearing loss, defined as the percentage of perfect hearing 
(100% excellent hearing and 0% deaf). We desire a 
0.10- significance level test with 95% statistical power and 
decide that the zone of equivalence is (−15%, 15%) and 
that the true difference in means does not exceed 0%. 
The SD observed from a similar population is 35. We plan 
to have an equal allocation to the two treatment groups 
(figures 1–3).
Tumour growth as the endpoint
The second endpoint concerning changes in tumour size 
(figure 4). The analysis indicates that a sample of about 
100 patients divided into two groups would be sufficient 
to demonstrate a difference in tumour size within 2 years 
at a power of 80.
Based on the power analysis, the study seemed to be 
feasible only to demonstrate the effect of GKRS on 
tumour volume, as the number of patients needed to 
demonstrate difference or similarity in hearing outcomes 
was unrealistically high.
Recruitment
Approximately 120 patients are referred to The Norwe-
gian National Unit for Vestibular Schwannomas per 
year. On a weekly basis, the treatment centre organises 
Figure 1 Hearing acuity as suggested endpoint.
Figure 2 Hearing acuity as suggested endpoint.
Figure 3 Hearing acuity as suggested endpoint.
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a multidisciplinary team meeting consisting of skull- base 
neurosurgeons, neurosurgeons primarily involved with 
radiosurgery, head and neck surgeons, neuroradiol-
ogists and VS nurses. At this meeting, all new referrals 
and patient follow- up/controls are discussed. Potential 
study participants will be identified at this meeting, and 
referred to their initial consultation at our treatment 
centre. Our experience is that these patients are easy to 
recruit to studies, and we believe recruiting 20–30 patients 
with small VS per year is feasible.
Allocation
Patients will be randomised to treatment groups 
using sequentially numbered, opaque sealed enve-
lopes (SNOSE).31 The SNOSE is the most accessible 
and straightforward method of maintaining allocation 
concealment. According to the Consolidated Standards 
of Reporting Trials (CONSORT) Statement, concealing 
the knowledge of upcoming group assignments prevents 
researchers from influencing which participants are 
assigned to a given intervention group.32 33 Permuted 
block randomisation will be performed in order to 
have an equal number of participants in each group 
in case the trial is stopped before the scheduled date. 
The V- REX will be stratified for two factors; age and 
whether the tumour was extra or intracanalicular. As we 
are uncertain whether how many patients harbour an 
intracanalicular tumour at the time of recruitment, we 
will block- randomise to ensure that an equal number 
of patients is allocated to each group. To ensure that 
the allocation sequence cannot be anticipated, we will 
use three block sizes (2, 4 and 6). In each block, an 
equal number of envelopes with a treatment card will 
be placed, and the block will be thoroughly shuffled. 
The SNOSE preparation is done by a statistician, and 
the enrolment and randomisation process is conducted 
by two study nurses.
Blinding (masking)
The observers will be blinded in the following outcome 
assessments:
 ► MRI assessment and volumetric measurements; 
patient name, identification number and examina-
tion date will be removed from MRI data prior to volu-
metric analyses.
 ► Patient interviews and assessments of subjective prob-
lems will be performed by a blinded doctor without 
knowing the patients name and treatment group. The 
patients will wear a scrub cap to hide any scars from a 
stereotactic frame.
 ► Clinical and neurological examinations, blinded for 
patient name and treatment group.
 ► Technicians at audiovestibular tests (audiometry, 
balance platform and nystagmography).
 ► Assessment of audiovestibular data.
Data collection
At their first outpatient visit, the potential study partic-
ipants will be recruited and randomised. If they agree, 
consent will be signed and baseline data are recorded 
including questionnaires and audiovestibular exam-
ination. An additional scan is done in patients who are 
randomised to CM. Patients who get randomised to GKRS 
return to the hospital within 2 months for treatment. The 
schedule is repeated after 1, 2, 3 and 4 years.
Figure 5 The Smartbrush function iPlan Brainlab Elements provide an interactive method for three- dimensional object creation 
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Clinical follow-up
All patients undergo annual clinical follow- up by a 
blinded physician, including patient interviews and clin-
ical examinations.
Radiological follow-up
As the primary endpoint is relative tumour size, an accu-
rate measure of tumour volume and changes thereof is 
mandatory. This will be obtained using a state- of- the- art 
MRI system suited for acquiring high- resolution (1 mm3), 
three- dimensional (3D) anatomical images. A 1.5 T 
imaging system that meets the required field homoge-
neity will be used for imaging. The image contrast will be 
T1 weighted with a gadolinium- based contrast agent, yet 
a T2- weighted image volume is also routinely acquired.
All subjects will undergo five MRI scans. The first being 
6 months prior to inclusion, followed by annual scans for 
4 years after inclusion. MRI taken at Gamma Knife treat-
ment will not be included in the study, as the stereotactic 
frame will be visible for the blinded observer. An iden-
tical imaging protocol will be acquired at each time point 
(prior to randomisation, on- site follow- up, 4- year annual 
follow- up), and image slices will be positioned according 
to anatomical landmarks in each patient to minimise vari-
ability across time. All 3D acquisitions will be performed 
with sagittal slicing to minimise artefacts, but will also 
be reformatted into coronal and axial views (1 mm slice 
thickness, no gap between slices) on the scanner system.
The subsequent imaging processing, that is, the esti-
mation of tumour volume and longitudinal changes 
thereof, will be performed using iPlan Brainlab Elements. 
By applying the Smartbrush function, which provides 
an instant interactive method for outlining pathology, 
the tumour area will be delineated on each image slice 
(figure 5). Potential non- tumour contrast- enhanced 
structures such as the transverse sinus, other neigh-
bouring vessels, and reactive dural enhancements will 
be deselected. A software algorithm will reconstruct a 
three- dimensional object based on the selected areas 
and present a detailed report including object volume 
in cubic centimetres (cm3). To assure that examinations 
are blinded to the observer, all scans will be deidenti-
fied for patient identification, MRI date and treatment 
group. All analyses will be performed centrally, that is, at 




Hearing is assessed with pure tone audiometry and 
measurement of speech discrimination. Pure tone average 
(of frequencies 0.5, 1, 2 and 4 kHz) and the maximum 
word recognition (%) is used for analysis.
Dynamic posturography
Dynamic posturography will be performed using the 
EquiTest (NeuroCom, Pleasanton, California) and the 
Sensory Organization Test protocol.2 This test results in a 
composite score, which is a weighted average of the equi-
librium score in six different sensory conditions: (1) eyes 
open, (2) eyes closed, (3) eyes open with sway referenced 
visual surroundings, (4) eyes open with sway referenced 
platform, (5) eyes closed with sway referenced platform 
and (6) eyes open with sway referenced visual surround-
ings and platform. Unsteadiness is defined as a composite 
score lower than the normative values integrated with the 
software supplied by the producer.
Video nystagmography
Patients undergo an examination with video nystagmog-
raphy and measurements of ocular smooth pursuit, saccades, 
positional nystagmus and bithermal caloric test. Caloric asym-
metry and absolute responses are used for further analysis.
Patient-reported outcome measures
All patients are asked to fill in a compilation of standardised 
questionnaires and assessment tools at baseline and at each 
annual visit. The questionnaires include the EuroQol 5D and 
the Penn Acoustic Neuroma Quality of Life Scale (PANQOL), 
which is a VS- specific QOL assessment tool consisting of 26 
questions with responses ranging from 1 to 5.34 Patients are 
also annually requested to report working status, annual 
income and use of the healthcare system.
Data management
Trial data will be entered into an approved protected data-
base (EMETRA, DIPS). The database server is externally 
managed, password protected, and access is only provided 
to the study nurse. All study participants will be given a 
unique identification number. The database will not contain 
a personal ID. Data containing such personal identification 
is kept at a ‘research server’ at HUH, following approval by 
REC. The key list is kept at a separate file on the research 
server only accessible to the study monitor.
Statistical methods
The difference between groups will be reported as mean 
(95% CI of OR for categories). The difference between 
groups from baseline until 4 years will be compared by paired 
(two- sided) t- test. Multiple regression will be used to perform 
a predictor analysis. All statistical tests will be two sided and 
significance will be considered at the 5% level. The primary 
analysis will be a comparison in tumour growth rate (VDT 
and relative change in tumour volume over a 4- year period). 
Interim analyses are not planned.




Regional Ethical Committee (REC West) in Norway has 
approved the trial (ID 23503). Patients are protected under 
the legislation that regulates the treatment of patients in 
Norwegian hospitals. They will be not subjected to proce-
dures other than those currently used as standard treatment. 
Each patient will sign a consent form after receiving oral 
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financial interest.
Adverse events will be investigated at each study visit and 
reported accordingly. One issue that has been particu-
larly dealt with is the risk of radiation- induced tumours. It 
is known that any amount of irradiation may increase the 
risk of neoplasia. The current knowledge about the risk of 
getting a CNS tumour after receiving radiosurgery is based 
on two studies.35 36 Rowe et al compared the development of 
secondary neoplasia in a large material of English patients 
receiving radiosurgery for benign intracranial lesions using 
data from the National Cancer Registry.35 They found that the 
incidence of neoplasia in irradiated patients was lower than 
expected when compared with the overall population, but 
the difference was not statistically significant. Wolf et al did a 
multicentre cohort study with near 5000 patients, and found 
the estimated risk of an intracranial secondary malignancy 
or malignant transformation of a benign tumour in patients 
treated with SRS to be similar to the risk of the general popu-
lation to have a primary CNS tumor.36 Therefore, if any, the 
increased risk of secondary neoplasia following radiosurgery 
seems to be very low. Except for this one issue, we are not 
aware of any safety hazards related to this study.
Dissemination policy
Trial methods and results will be reported according to 
the CONSORT 2010 guidelines. The results of the study 
are expected to be published in a peer- reviewed journal in 
2022/2023. The authors will present the study at national and 
international conferences related to the fields of Neurosur-
gery and Otology. The research findings will also be dissemi-
nated to all study participants and at our national courses for 
patients with VS.
There are no restrictions preventing the disclosure and 
publication of the results from the research project.
A 10- year follow- up may be considered at the study end. 
Long- term data for patients with VS are scarce. Patients are 
assumed to have a normal life expectancy, and a survey of 
tumours and symptoms after a long time is desirable.
DISCUSSION
The level of evidence for choosing a treatment strategy for 
small VS is poor. Two studies comparing GKRS and CM indi-
cate a significant effect of GKRS in reducing tumour growth, 
but fewer differences in hearing and problem outcomes.16 17 
None of the studies are blinded or randomised, allowing for 
bias.
GKRS has been used for more than three decades, and 
worldwide an increasing number of patients with VS receive 
treatment by GKRS, which is now the most- used treatment. 
The aim of GKRS is tumour control, defined as either 
reduced or unchanged tumour volume. The majority of 
centres report tumour control rates between 89% and 100%, 
but few centres report observation periods longer than 
5 years. The tumour growth rates before GKRS are usually 
unknown in reported series. Consequently, a proportion of 
treated tumours might have remained unchanged without 
treatment at all.
We, therefore, believe that prospective comparative 
studies need to be carried out before patients can be 
advised on a statistical basis about the relative merits 
of CM or GKRS in relation to both growth and hearing 
preservation.
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